National Consensus for Screening, Diagnosis and Management of Hepatocellular Carcinoma in Panama, 2022
DOI:
https://doi.org/10.17140/CSMMOJ-7-133Keywords:
Hepatocellular carcinoma, Guidelines, Consensus, PanamaAbstract
Introduction
Hepatocellular carcinoma (HCC) is considered the main primary neoplasm of the liver and its incidence is expected to increase in
the next years. HCC is frequently associated with chronic liver disease secondary to hepatitis B or C infections, as well to alcohol
abuse, fatty liver and metabolic syndrome. Multidisciplinary and individualized management has been shown to improve clinical
outcome; nevertheless, in Panama and others Latin-American countries, there is no clear consensus for the management of this
disease.
Methodology
Using Appraisal of Guidelines for REsearch and Evaluation II (AGREE II) methodology and the Institute of Medicine (IOM)
criteria, we developed a multidisciplinary consensus for the management of hepatocarcinoma patients in Panama.
Results
This document synthesizes the current evidence on risk factors in conjunction with recommendations on the management of
early, advanced and terminal disease. All healthcare personnel involved in the approach and treatment of hepatocarcinoma in
Panama can find utility and applicability in their daily practice.
Conclusion
Here, we present the first National Consensus for the Screening, Diagnosis and Treatment of Hepatocellular Carcinoma in
Panama.
References
El-Serag HB. Epidemiology of viral hepatitis and hepatocel-lular carcinoma. Gastroenterology. 2012; 142: 1264-1273.e1. doi: 10.1053/j.gastro.2011.12.061
Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic steato-hepatitis is the fastest growing cause of hepatocellular carcino-ma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019; 17(4): 748-755.e3. doi: 10.1016/j.cgh.2018.05.057
Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B pa-tients receiving nucleos(t)ide therapy: A systematic review. J Hepa-tol. 2010; 53: 348-356. doi: 10.1016/j.jhep.2010.02.035
Ioannou GN, Beste LA, Green PK, et al. Increased risk for 12 Cukier M, et al hepatocellular carcinoma persists up to 10 years after HCV eradi-cation in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology. 2019; 157: 1264-1278.e4. doi: 10.1053/j.gas-tro.2019.07.033
Kanwal F, Kramer JR, Asch SM, Cao Y, Li L, El-Serag HB. Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents. Hepatology. 2020; 71: 44- 55. doi: 10.1002/hep.30823
Bruno S, Stroffolini T, Colombo M, et al. Sustained virologi-cal response to interferon-alpha is associated with improved out-come in HCV-related cirrhosis: A retrospective study. Hepatology. 2007; 45: 579-587. doi: 10.1002/hep.21492
Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: A meta-analysis of observational studies. Ann Intern Med. 2013; 158: 329-337. doi: 10.7326/0003- 4819-158-5-201303050-00005
Chen C-J, Yang H-I, Su J, et al. Risk of hepatocellular car-cinoma across a biological gradient of serum hepatitis B. virus DNA level. JAMA. 2006; 295: 65-73. doi: 10.1001/jama.295.1.65
Brouwers MC, Kho ME, Browman GP, et al. AGREE II: Advancing guideline development, reporting and evaluation in health care. CMAJ. 2010; 182(18): E839-E842. doi: 10.1503/ cmaj.090449
Kulik L, El-Serag HB. Epidemiology and management of he-patocellular carcinoma. Gastroenterology. 2019; 156(2): 477-491.e1. doi: 10.1053/j.gastro.2018.08.065
Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Rob-erts LR. A global view of hepatocellular carcinoma: trends, risk, prevention, and management. Nat Rev Gastroenterol Hepatol. 2019; 16(10): 589-604. doi: 10.1038/s41575-019-0186-y
Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk fac-tors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol. 2018; 68(3): 526-549. doi: 10.1016/j. jhep.2017.09.016
Konyn P, Ahmed A, Kim D. Current epidemiology in hepato-cellular carcinoma. Expert Rev Gastroenterol Hepatol. 2021; 15(11): 1295-1307. doi: 10.1080/17474124.2021.1991792
McIntyre CA, Chou JF, Gonen M, et al. Hepatocellular carci-noma in patients with no identifiable risk factors. HPB (Oxford). 2021; 23(1): 118-126. doi: 10.1016/j.hpb.2020.05.005
Massarweh NN, El-Serag HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control. 2017; 24(3): 1073274817729245. doi: 10.1177/1073274817729245
Frager SZ, Schwartz JM. Hepatocellular carcinoma: Epidemi-ology, screening, and assessment of hepatic reserve. Curr Oncol. Systematic Review | Volume 7 | Number 1| 2020; 27(Suppl 3): S138-S143. doi: 10.3747/co.27.7181
Liu XN, Cui DN, Li YF, Liu YH, Liu G, Liu L. Multiple “Omics” data-based biomarker screening for hepatocellular car-cinoma diagnosis. World J Gastroenterol. 2019; 25(30): 4199-4212. doi: 10.3748/wjg.v25.i30.4199
Sachar Y, Brahmania M, Dhanasekaran R, Congly SE. Screen-ing for hepatocellular carcinoma in patients with hepatitis B. Vi-ruses. 2021; 13(7): 1318. doi: 10.3390/v13071318
Clark T, Maximin S, Meier J, Pokharel S, Bhargava P. Hepato-cellular carcinoma: Review of epidemiology, screening, imaging diagnosis, response assessment, and treatment. Curr Probl Diagn Radiol. 2015; 44(6): 479-486. doi: 10.1067/j.cpradiol.2015.04.004
Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. 2020; 371: m3544. doi: 10.1136/bmj.m3544
Ganne-Carrié N, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease. J Hepatol. 2019; 70(2): 284- 293. doi: 10.1016/j.jhep.2018.10.008
Yaprak O, Akyildiz M, Dayangac M, et al. AFP level and his-tologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2012; 11(3): 256-261. doi: 10.1016/s1499-3872(12)60157-x
Eilard MS, Holmberg E, Naredi P, Söderdahl G, Rizell M. Addition of alfa fetoprotein to traditional criteria for hepato-cellular carcinoma improves selection accuracy in liver trans-plantation. Scand J Gastroenterol. 2018; 53(8): 976-983. doi: 10.1080/00365521.2018.1488180
Ayuso C, Rimola J, García-Criado Á. Imaging of HCC. Abdom Imaging. 2012; 37(2): 215-230. doi: 10.1007/s00261-011-9794-x
Hoffmann-Eßer W, Siering U, Neugebauer EAM, Brockhaus AC, Lampert U, Eikermann M. Guideline appraisal with AGREE II: Systematic review of the current evidence on how users han-dle the 2 overall assessments. PLoS One. 2017; 12(3): e0174831. doi: 10.1371/journal.pone.0174831
Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular car-cinoma. Nat Rev Dis Primers. 2021; 7(1): 6. doi: 10.1038/s41572- 020-00240-3
Loomba R, Lim JK, Patton H, El-Serag HB. AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: Expert review. Gastroenterology. 2020; 158(6): 1822-1830. doi: 10.1053/j. gastro.2019.12.053
Ding H, Tu H, Qu C, et al. Guideline Open Access Hepatoma Research Guideline for stratified screening and surveillance in pa-tients with high risk of primary liver cancer (2020). Hepatoma Res. 2021; 7: 17. doi: 10.20517/2394-5079.2021.13 Systematic Review | Volume 7 | Number 1| Cukier M, et al
Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice Guid-ance by the American Association for the study of liver diseases. Hepatology. 2018; 68(2): 723-750. doi: 10.1002/hep.29913
Cheung TTT, Kwok PCH, Chan S, et al. Hong Kong con-sensus statements for the management of unresectable he-patocellular carcinoma. Liver Cancer. 2018; 7(1): 40-54. doi: 10.1159/000485984
Lubel JS, Roberts SK, Strasser SI, et al. Australian recom-mendations for the management of hepatocellular carcinoma: A consensus statement. Med J Aust. 2021; 214(10): 475-483. doi: 10.5694/mja2.50885
Ozkan H, Kamran M, Raees A, Jafri W. Updates on the di-agnosis and management of hepatocellular carcinoma. Euroasian J Hepatogastroenterol. 2021; 11(1): 32-40. doi: 10.5005/jp-jour-nals-10018-1335
Ayuso C, Rimola J, Vilana R, et al. Diagnosis and staging of hepatocellular carcinoma (HCC): Current guidelines. Eur J Radiol. 2018; 101: 72-81. doi: 10.1016/j.ejrad.2018.01.025
Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 389(10064): 56-66. doi: 10.1016/ S0140-6736(16)32453-9
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocel-lular carcinoma: A randomised phase 3 non-inferiority trial. Lancet. 2018; 391(10126): 1163-1173. doi: 10.1016/S0140- 6736(18)30207-1
Reig M, Forner A, Rimola J, et al. BCLC strategy for progno-sis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022; 76(3): 681-693. doi: 10.1016/j.jhep.2021.11.018
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4): 378-390. doi: 10.1056/NEJMoa0708857
Hawkins MA, Dawson LA. Radiation therapy for hepatocel-lular carcinoma: From palliation to cure. Cancer. 2006; 106: 1653- 1663. doi: 10.1002/cncr.21811
Sze WM, Shelley M, Held I, Mason M. Palliation of metastatic bone pain: Single fraction versus multifraction radiotherapy (Re-view). Cochrane Database Syst Rev. 2004; 2002(2): CD004721. doi: 10.1002/14651858.CD004721
Muller-Riemenschneider F, Bockelbrink A, Ernst I, et al. Ste-reotactic radiosurgery for the treatment of brain metastases. Ra-diother Oncol. 2009; 91: 67-74. doi: 10.1016/j.radonc.2008.12.001
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizum-ab in unresectable hepatocellular Carcinoma. N Eng J Med. 2020; 382(20): 1894-1905. doi: 10.1056/NEJMoa1915745
Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma: An EASL position paper. J Hepatol. 2021; 75(4): 960-974. doi: 10.1016/j.jhep.2021.07.004
Jindal A, Thadi A, Shailubhai K. Hepatocellular carcinoma: Etiology and current and future drugs. J Clin Exp Hepatol. 2019; 9(2): 221-232. doi: 10.1016/j.jceh.2019.01.004
Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin On-col. 2018; 15(10): 599-616. doi: 10.1038/s41571-018-0073-4
Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic ther-apy for advanced hepatocellular carcinoma: ASCO Guideline. J Clin Oncol. 2020; 38(36): 4317-4345. doi: 10.1200/JCO.20.02672
Syed YY. Ramucirumab: A review in hepatocellular carcinoma. Drugs. 2020; 80(3): 315-322. doi: 10.1007/s40265-020-01263-6
Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20(2): 282-296. doi: 10.1016/S1470-2045(18)30937-9
Carvalho JR, Vasconcelos M, Marques da Costa P, et al. Iden-tifying palliative care needs in a Portuguese liver unit. Liver Int. 2018; 38(11): 1982-1987. doi: 10.1111/liv.13865 Submit your article to this journal | https://openventio.org/submit-manuscript/ 14 Cukier M, et al
Patel AA, Woodrell C, Ufere NN, et al. Developing priorities for palliative care research in advanced liver disease: A multidis-ciplinary approach. Hepatol Commun. 2021; 5(9): 1469-1480. doi: 10.1002/hep4.1743
Atiq O, Tiro J, Yopp AC, et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis HHS public access. Hepatology. 2017; 65(4): 1196-1205. doi: 10.1002/hep.28895
Kumar M, Panda D. Role of supportive care for terminal stage hepatocellular carcinoma. J Clin Exp Hepatol. 2014; 4: S130-S139. doi: 10.1016/j.jceh.2014.03.049
Firkins JL, Tarter R, Driessnack M, Hansen L. A closer look at quality of life in the hepatocellular carcinoma literature. Qual Life Res. 2021; 30(6): 1525-1535. doi: 10.1007/s11136-021-02789-2
Laube R, Sabih AH, Strasser SI, Lim L, Cigolini M, Liu K. Palliative care in hepatocellular carcinoma. J Gastroenterol Hepatol. 2021; 36(3): 618-628. doi: 10.1111/jgh.15169
Hansen L, Rosenkranz SJ, Vaccaro GM, Chang MF. Patients with hepatocellular carcinoma near the end of life: A longitudinal qualitative study of their illness experiences. Cancer Nurs. 2015; 38(4): E19-E27. doi: 10.1097/NCC.0000000000000188
Bai M, Reynolds NR, McCorkle R. The promise of clini-cal interventions for hepatocellular carcinoma from the west to mainland China. Palliat Support Care. 2013; 11(6): 503-522. doi: 10.1017/S1478951512001137 Systematic Review | Volume 7 | Number 1|
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Cancer Studies and Molecular Medicine (CSMM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
